Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin. Part 2: Clinical studies

Science Translational Medicine

Volumn 2, Issue 59, 2010, Pages

  Lanzani, Chiara ^a   Citterio, Lorena ^a   Glorioso, Nicola ^b   Manunta, Paolo ^a   Tripodi, Grazia ^c   Salvi, Erika ^d,e   Carpini, Simona Delli ^a   Ferrandi, Mara ^c   Messaggio, Elisabetta ^a   Staessen, Jan A ^f,g   Cusi, Daniele ^e,h   Macciardi, Fabio ^h,i   Argiolas, Giuseppe ^b   Valentini, Giovanni ^j   Ferrari, Patrizia ^c   Bianchi, Giuseppe ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c Prassis Sigma Tau Research Institute   (Italy)

^d KOS Genetic   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h Genomics and Bioinformatics Unit   (Italy)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Sigma Tau SpA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ABC TRANSPORTER A1; ADDUCIN; ADDUCIN 1; ADDUCIN 3; ALPHA ADDUCIN; HYDROCHLOROTHIAZIDE; LANOSTEROL SYNTHASE; LOSARTAN; OUABAIN; PLACEBO; ROSTAFUROXIN; STEROID DELTA ISOMERASE; UNCLASSIFIED DRUG; 17 (3 FURYL) 5BETA ANDROSTANE 3,14,17 TRIOL; 17-(3-FURYL)-5BETA-ANDROSTANE-3,14,17-TRIOL; ANDROSTANE DERIVATIVE; ANTIHYPERTENSIVE AGENT; CALMODULIN BINDING PROTEIN; MUTANT PROTEIN; MUTASE;

ABCB1 GENE; ADD1 GENE; ADD3 GENE; ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE; GENETIC VARIABILITY; HSD3B1 GENE; HUMAN; HUMAN TISSUE; HYPERTENSION; LSS GENE; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GENE LOCUS; GENETIC TRANSFECTION; GENETICS; KIDNEY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLE; TIME;

ANDROSTANOLS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALMODULIN-BINDING PROTEINS; FEMALE; GENETIC LOCI; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INTRAMOLECULAR TRANSFERASES; KIDNEY; LOSARTAN; MALE; MIDDLE AGED; MUTANT PROTEINS; OUABAIN; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; SYSTOLE; TIME FACTORS; TRANSFECTION;

EID: 84995528762     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001814     Document Type: Article

References (45)

1. M. Ferrandi, I. Molinari, L. Torielli, G. Padoani, S. Salardi, M. P. Rastaldi, P. Ferrari, G. Bianchi, Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin. Part 1: Experimental studies. Sci. Transl. Med. 2, 59ra86 (2010).
2. G. Bianchi, Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: From gene polymorphism to clinical symptoms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, R1536-R1549 (2005).
3. L. Citterio, C. Lanzani, P. Manunta, G. Bianchi, Genetics of primary hypertension: The clinical impact of adducin polymorphisms. Biochim. Biophys. Acta 1802, 1285-1298 (2010).
4. A. C. Guyton, T. G. Coleman, H. J. Granger, Circulation: Overall regulation. Annu. Rev. Physiol. 34, 13-46 (1972).
5. S. Swart, R. F. Bing, J. D. Swales, H. Thurston, Plasma renin in long-term diuretic treatment of hypertension: Effect of discontinuation and restarting therapy. Clin. Sci. 63, 121-125 (1982).
6. J. R. Paull, R. E. Widdop, Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. J. Hypertens. 19, 1393-1402 (2001).
7. H. M. Qazzaz, Z. Cao, D. D. Bolanowski, B. J. Clark, R. Valdes Jr., De novo biosynthesis and radiolabeling of mammalian digitalis-like factors. Clin. Chem. 50, 612-620 (2004).
8. I. A. de Lannoy, M. Silverman, The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 189, 551-557 (1992).
9. W. Schoner, G. Scheiner-Bobis, Endogenous and exogenous cardiac glycosides: Their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 293, C509-C536 (2007).
10. J. R. Murrell, J. D. Randall, J. Rosoff, J. L. Zhao, R. V. Jensen, S. R. Gullans, G. T. Haupert Jr., Endogenous ouabain: Upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal. Circulation 112, 1301-1308 (2005).
11. J. A. Staessen, T. Kuznetsova, R. Acceto, A. Bacchieri, E. Brand, M. Burnier, H. Celis, L. Citterio, P. W. de Leeuw, J. Filipovský, A. Fournier, K. Kawecka-Jaszcz, P. Manunta, Y. Nikitin, E. T. O'Brien, J. Redón, L. Thijs, P. Ferrari, G. Valentini, G. Bianchi, OASIS-HT: Design of a pharmacogenomic dose-finding study. Pharmacogenomics 6, 755-775 (2005).
12. G. Tripodi, L. Citterio, T. Kouznetsova, C. Lanzani, M. Florio, R. Modica, E. Messaggio, J. M.Hamlyn, L. Zagato, G. Bianchi, J. A. Staessen, P. Manunta, Steroid biosynthesis and renal excretion in human essential hypertension: Association with blood pressure and endogenous ouabain. Am. J. Hypertens. 22, 357-363 (2009).
13. K. L. Fung, M. M. Gottesman, A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta 1794, 860-871 (2009).
14. M. Cwynar, J. A. Staessen, M. Tichá, T. Nawrot, L. Citterio, T. Kuznetsova, W. Wojciechowska, K. Stolarz, J. Filipovský, K. Kawecka-Jaszcz, T. Grodzicki, H. A. Struijker-Boudier, L. Thijs, L. M. Van Bortel, G. Bianchi; European Project On Genes in Hypertension (EPOGH) Investigators, Epistatic interaction between α- and γ-adducin influences peripheral and central pulse pressures in white Europeans. J. Hypertens. 23, 961-969 (2005).
15. C. Lanzani, L. Citterio, M. Jankaricova, M. T. Sciarrone, C. Barlassina, S. Fattori, E. Messaggio, C. D. Serio, L. Zagato, D. Cusi, J. M. Hamlyn, A. Stella, G. Bianchi, P. Manunta, Role of the adducin family genes in human essential hypertension. J. Hypertens. 23, 543-549 (2005).
16. P. Manunta, M. Maillard, C. Tantardini, M. Simonini, C. Lanzani, L. Citterio, P. Stella, N. Casamassima, M. Burnier, J. M. Hamlyn, G. Bianchi, Relationships among endogenous ouabain, α-adducin polymorphisms and renal sodium handling in primary hypertension. J. Hypertens. 26, 914-920 (2008).
17. J. A. Staessen, L. Thijs, K. Stolarz-Skrzypek, A. Bacchieri, J. Burton, E. Degli Espositi, P. W. de Leeuw, T. M. Dluzniewski, N. Glorioso, A. Januszewics, P. Manunta, V. Milyagin, Y. Nikitin, M. Souček, C. Lanzani, L. Citterio, M. Timio, A. Tykarski, P. Ferrari, G. Valentini, K. Kawecka-Jaszcz, G. Bianchi, Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): A randomized placebo-controlled phase 2 dose-finding study of rostafuroxin. Trials, in press.
18. P. Ferrari, L. Torielli, M. Ferrandi, G. Padoani, L. Duzzi, M. Florio, F. Conti, P. Melloni, L. Vesci, N. Corsico, G. Bianchi, PST2238: A new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J. Pharmacol. Exp. Ther. 285, 83-94 (1998).
19. P. Ferrari, M. Ferrandi, G. Tripodi, L. Torielli, G. Padoani, E. Minotti, P. Melloni, G. Bianchi, PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J. Pharmacol. Exp. Ther. 288, 1074-1083 (1999).
20. M. Boddi, L. Poggesi, M. Coppo, N. Zarone, S. Sacchi, C. Tania, G. G. Neri Serneri, Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. Hypertension 31, 836-842 (1998).
21. B. M. Psaty, C. Doggen, H. L. Vos, J. P. Vandenbroucke, F. R. Rosendaal, Association of the α-adducin polymorphism with blood pressure and risk of myocardial infarction. J. Hum. Hypertens. 14, 95-97 (2000).
22. A. C. Morrison, M. S. Bray, A. R. Folsom, E. Boerwinkle, ADD1 460W allele associated with cardiovascular disease in hypertensive individuals. Hypertension 39, 1053-1057 (2002).
23. B. M. Psaty, N. L. Smith, S. R. Heckbert, H. L. Vos, R. N. Lemaitre, A. P. Reiner, D. S. Siscovick, J. Bis, T. Lumley, W. T. Longstreth Jr., F. R. Rosendaal, Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 287, 1680-1689 (2002).
24. X. F. Dou, H. Y. Zhang, X. H. Huang, X. N. Liu, Z. Y. Ju, K. Sun, D. W. Wang, Y. H. Liao, A. Q. Ma, Z. M. Zhu, B. R. Zhao, J. Z. Zhao, Y. Song, L. Zhang, R. T. Hui, α-Adducin gene G/W460 polymorphism is associated with intracerebral hemorrhage in Chinese. Zhonghua Yi Xue Za Zhi 84, 186-188 (2004).
25. Y. Li, L. Thijs, T. Kuznetsova, L. Zagato, H. Struijker-Boudier, G. Bianchi, J. A. Staessen, Cardiovascular risk in relation to α-adducin Gly460Trp polymorphism and systolic pressure: A prospective population study. Hypertension 46, 527-532 (2005).
26. M. J. van Rijn, M. J. Bos, M. Yazdanpanah, A. Isaacs, A. Arias-Vásquez, P. J. Koudstaal, A. Hofman, J. C. Witteman, C. M. van Duijn, M. M. Breteler, α-Adducin polymorphism, atherosclerosis, and cardiovascular and cerebrovascular risk. Stroke 37, 2930-2934 (2006).
27. M. Yazdanpanah, F. A. Sayed-Tabatabaei, A. Hofman, Y. S. Aulchenko, B. A. Oostra, B. H. C. Stricker, H. A. Pols, S. W. Lamberts, J. C. Witteman, J. A. Janssen, C. M. van Duijn, The α-adducin gene is associated with macrovascular complications and mortality in patients with type 2 diabetes. Diabetes 55, 2922-2927 (2006).
28. S.H. Cha, H. T. Kim, Y. Jang, S. Park, J. J. Kim, M. Y. Song, J.H. Park, H. J. Ryu,H. Y. Park, S. J. Yoon, K. Kimm, J. K. Lee, B. Oh, Association of α-adducin Gly460Trp polymorphism with coronary artery disease in a Korean population. J. Hypertens. 25, 2413-2420 (2007).
29. M. H. Zafarmand, Y. T. van der Schouw, D. E. Grobbee, P. W. de Leeuw, M. L. Bots, α-Adducin Gly460Trp variant increases the risk of stroke in hypertensive Dutch women. Hypertension 51, 1665-1670 (2008).
30. T. Gerhard, Y. Gong, A. L. Beitelshees, X. Mao, M. T. Lobmeyer, R. M. Cooper-DeHoff, T. Y. Langaee, N. J. Schork, M. D. Shriver, C. J. Pepine, J. A. Johnson; INVEST Investigators, α-Adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVESTGENES). Am. Heart J. 156, 397-404 (2008).
31. P. Manunta, M. Ferrandi, G. Bianchi, J. M. Hamlyn, Endogenous ouabain in cardiovascular function and disease. J. Hypertens. 27, 9-18 (2009).
32. A. J. Muslin, MAPK signalling in cardiovascular health and disease: Molecular mechanisms and therapeutic targets. Clin. Sci. 115, 203-218 (2008).
33. D. K. Arnett, S. A. Claas, A. I. Lynch, Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? Curr. Opin. Cardiol. 24, 333-339 (2009).
34. J. A. Johnson, Pharmacogenomics of antihypertensive drugs: Past, present and future. Pharmacogenomics 11, 487-491 (2010).
35. P. C. Phillips, Epistasis - the essential role of gene interactions in the structure and evolution of genetic systems. Nat. Rev. Genet. 9, 855-867 (2008).
36. D. B. Goldstein, Common genetic variation and human traits. N. Engl. J. Med. 360, 1696-1698 (2009).
37. D. S. Wald, M. Law, J. K. Morris, J. P. Bestwick, N. J. Wald, Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122, 290-300 (2009).
38. http://clinicaltrial.gov.
39. International HapMap Project; http://www.hapmap.org.
40. A. Villagra, N. Ulloa, X. Zhang, Z. Yuan, E. Sotomayor, E. Seto, Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression. J. Biol. Chem. 282, 35457-35470 (2007).
41. M. Ferrandi, P. Manunta, S. Balzan, J. M. Hamlyn, G. Bianchi, P. Ferrari, Ouabain-like factor quantification in mammalian tissues and plasma: Comparison of two independent assays. Hypertension 30, 886-896 (1997).
42. Tagger; http://www.broad.mit.edu/mpg/tagger.
43. Haploview 3.2; http://www.broad.mit.edu/mpg/haploview.
44. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
45. Acknowledgments: We thank R. Modica for cell culture experiments; N. Casamassima for help in DNA extraction; G. Dell'Antonio and R. Bertini for human kidney sample recruitment; A. Bacchieri and F. Cenci for calculation of carryover effect; P. Barassi for ouabain measurements; C. Scotti for technical assistance; and OASIS-HT Investigators: H. Celis (Leuven), J. Filipovský (Pilsen), M. Souček, J. Vítovec, J. Špinar (Brno), J. Barton, C. Kelly (Galway), G. Basso (Schio), E. Casiglia, V. Tikhonoff (Padua), E. Degli Espositi (Ravenna), M. Timio (Foligno), P. W. de Leeuw (Maastricht), M. Krekels (Sittard), M. Diuzniewski, A. Januszewicz (Warsaw), T. Grodzicki, K. Kawecka-Jaszcz, A. Olszanecka, K. Stolarz-Skrzpek, M. Klocek, W. Piwowarska (Krakow), K. Narkiewicz, B. Wyrzkowski (Gdansk), A. Tykarski (Poznan), Y. Nikitin (Novosibirsk), V. Milyagin (Smolensk), S. Nedogoda (Volgograd), J. Brugljan, R. Acceto (Ljubljana), C. Calvo-Gomez, A. Pose-Reino (Santiago de Compostela), and F. Hernández-Menárgez (Murcia). Funding: This work was supported by sigma-tau and by Rostaquo/sigma-tau SAR-IDZ-01/2009. Author contributions: C.L., N.G., P.M., G.A., and G.V. followed the clinical studies; G.T. and M.F. performed experiments in cultured cells; L.C. and S.D.C. performed the genotyping and human expression analysis; E.M. coordinated the biological sample collection of study 1; C.L., L.C., E.S., and F.M. performed the statistical analysis; P.M., J.A.S., P.F., and G.B. were involved in project planning; J.A.S., D.C., P.F., and G.B. participated in manuscript preparation. Competing interests: G.T., G.V., and P.F. are employees of Prassis sigma-tau. G.B. is a paid consultant to Prassis sigma-tau. C.L., L.C., N.G., P.M., E.S., S.D.C., E.M., J.A.S., D.C., F.M., and G.A. declare that they have no competing financial interests. Accession numbers: Study 1 (OASIS-HT study) is registered as clinical trial NCT 00415038. The raw data for study 1, study 2, and study 2003 are available in the Supplementary Material.